{
    "symbol": "XNCR",
    "quarter": 4,
    "year": 2022,
    "date": "2023-02-23 23:11:08",
    "content": " Your line is open. Your line is open. So the way we think about the CD3s versus CD28 is with the CD3 is it's basically a more of an artificial immunity, or you're just taking advantage of any, any T-cell around, engaging it through CD3 and recruiting it to attack the tumor cells with the CD28, because it's just providing signal to that's equally intriguing biology, because now you'd that signal to have to build off an endogenous signal one, which comes from neoantigen, T cell reckoning mission by the T-cells. Your line is open. And regarding B7-H3 versus B7-H4 I think we'll focus on what we find attractive about B7-H3, it's expressed in multiple tumor types, it has a good differential across multiple tissues for tumor versus normal tissue, it's absent or very, undetectable expression, I should say, in certain problematic tissues like the central nervous system, brain and nerves that I think that makes it very attractive, the B7-H4 is a target I'm starting to see pop up and I think there's very little data or come in on it. Your line is open. Your line is open. And one moment for our next question. Your line is open. I have one question that's essentially a follow-up to something that Etzer had asked, but regarding XmAb808, encouraging to see that you guys are combining this with pembro, but perhaps given you have other pipeline assets in the clinic that are also going prostate cancer with similar mechanisms such as vudalimab. And one moment for our next question. Your line is open. And one moment for our next question. Your line is open. Your line is open. And one moment for our next question. Your line is open. Your line is open. Your line is open."
}